The role of CA125 in clinical practice

Background: CA125 is a high molecular weight glycoprotein, which is expressed by a large proportion of epithelial ovarian cancers. The sensitivity and specificity of CA125 are poor and there are no guidelines produced by the Royal College of Pathologists or the Association of Clinical Biochemists to aid clinicians and laboratories in its most appropriate use. Aim: To identify the patient population having a CA125 measurement and to determine its contribution to individual patient management. Methods: A retrospective case note audit looking at patients who had a CA125 measurement performed between April 2000 and April 2002. Results: The study comprised 799 patients; 751 (94%) were female and 48 (6%) male; 221 (29%) females and 22 (46%) males had an abnormal result. CA125 was mainly used to investigate a wide range of signs and symptoms, and few tests were for follow up or screening of ovarian cancer. In female patients having a CA125 for suspicion of malignancy/ovarian cancer, only 39 (20%) of the abnormal results were caused by ovarian cancer. False positive results were largely caused by another malignancy (48 cases; 26%), benign ovarian disease (26 cases; 14%), and benign gynaecological conditions, particularly leiomyomas (18 cases; 9%). The specificity of CA125 for ovarian cancer increased with concentrations >1000 kU/litre. Conclusions: These results confirm the high false positive rate and poor sensitivity and specificity associated with CA125. The substantial inappropriate usage of CA125 has led to results that are useless to the clinician, have cost implications, and add to patient anxiety and clinical uncertainty.

[1]  C. Coca,et al.  Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer. , 2003, Anticancer research.

[2]  P. Visintainer,et al.  CA 125 levels in the preoperative assessment of advanced-stage uterine cancer. , 2003, American journal of obstetrics and gynecology.

[3]  M. Provencio,et al.  Cancer Antigen 125 Associated With Multiple Benign and Malignant Pathologies , 2003, Annals of Surgical Oncology.

[4]  G. Rayman,et al.  Lesson of the week: Hypothyroidism mimicking intra-abdominal malignancy. , 2002, BMJ.

[5]  R. Mannel,et al.  Ascites as a predictor of ovarian malignancy. , 2002, Gynecologic oncology.

[6]  P. Kenemans,et al.  The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. , 2002, American journal of obstetrics and gynecology.

[7]  B. Nilsson,et al.  The significance of serum CA 125 elevation in malignant and nonmalignant diseases. , 2002, Gynecologic oncology.

[8]  F. Ece,et al.  The value of Ca 125 in the evaluation of tuberculosis activity. , 2001, Respiratory medicine.

[9]  P. Buamah.  Benign conditions associated with raised serum CA‐125 concentration , 2000, Journal of surgical oncology.

[10]  M. Predanic.  Differentiating tubal abortion from viable ectopic pregnancy with serum CA-125 and beta-human chorionic gonadotropin determinations. , 2000, Fertility and sterility.

[11]  M. Heikinheimo,et al.  Serum tumor marker CA 125 is an early and sensitive indicator of veno-occlusive disease in children undergoing bone marrow transplantation. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  G. Demir,et al.  Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma. , 1999, American journal of clinical oncology.

[13]  J. Alcázar,et al.  Transvaginal color Doppler ultrasonography and CA‐125 in suspicious adnexal masses , 1999, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[14]  R. Bast,et al.  Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. , 1999, Gynecologic oncology.

[15]  H. Meden,et al.  CA 125 in Benign Gynecological Conditions , 1998, The International journal of biological markers.

[16]  L. Blumenson,et al.  Serum CA-125 measurements > 65 U/mL. Clinical value. , 1997, The Journal of reproductive medicine.

[17]  U. Patel,et al.  Benign extraovarian mimics of ovarian cancer. Distinction with imaging studies. , 1997, Clinical imaging.

[18]  R. Troiano,et al.  Correlation of Findings on Transvaginal Sonography with Serum CA 125 Levels , 1997, AJR. American journal of roentgenology.

[19]  Tore Halvorsen,et al.  Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre‐operative diagnosis of pelvic masses , 1996, British journal of obstetrics and gynaecology.

[20]  G. Rustin.  The Clinical Value of Tumour Markers in the Management of Ovarian Cancer , 1996, Annals of clinical biochemistry.

[21]  J. Magrina,et al.  Benign gynecologic conditions associated with a CA-125 level > 1,000 U/mL. A case report. , 1996, The Journal of reproductive medicine.

[22]  M R Conaway,et al.  Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. , 1995, Gynecologic oncology.

[23]  G. Bodor,et al.  CA-125 concentrations in malignant and nonmalignant disease. , 1991, Clinical chemistry.

[24]  R. Bast,et al.  Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.